As anaplastic lymphoma kinase (ALK)-tyrosine kinase inhibitors (TKIs) dramatically improve progression-free survival compared to cytotoxic agents [3–6], ALK-TKIs are commonly used for ALK fusion protein-positive non-small cell lung cancer unless the tumor becomes resistant to the drug. Here, ALK is linked to non-small cell lung carcinoma.